To our knowledge, the VICTOR-2 study is the first multicenter prospective trial testing the fully oral metronomic combination of VNR and CAPE in a population of advanced HER2-negative breast cancer patients with pre-specified analyses of efficacy and safety according to biological subtype, line of treatment, and site of metastatic disease. Here, ERBB2 is linked to breast cancer.